102 related articles for article (PubMed ID: 23599183)
1. The best clinical paper on multiple sclerosis in 2012: commentary.
Hutchinson M
Mult Scler; 2013 Apr; 19(5):522-3. PubMed ID: 23599183
[No Abstract] [Full Text] [Related]
2. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Goodin DS
Neurology; 2006 Oct; 67(7):1313-4. PubMed ID: 17030783
[No Abstract] [Full Text] [Related]
3. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Durelli L; Barbero P; Clerico M;
Neurology; 2006 Dec; 67(12):2264; author reply 2264-5. PubMed ID: 17190964
[No Abstract] [Full Text] [Related]
4. Landmark papers in multiple sclerosis.
Cross AH
Neurology; 2001 Dec; 57(12 Suppl 5):S1-2. PubMed ID: 11902588
[No Abstract] [Full Text] [Related]
5. [PRISMS study. Interferon beta-1a therapy in relapsing-remitting multiple sclerosis].
Limmroth V
Internist (Berl); 2001 Feb; 42(2):305-7. PubMed ID: 11244885
[No Abstract] [Full Text] [Related]
6. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing/remitting multiple sclerosis.
Deisenhammer F; Giovannoni G
Mult Scler; 2004 Dec; 10(6):713-4; author reply 715. PubMed ID: 15584500
[No Abstract] [Full Text] [Related]
8. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Reder AT; Ebers GC; Traboulsee A; Li D; Langdon D; Goodin DS; Bogumil T; Beckmann K; Konieczny A;
Neurology; 2010 Jun; 74(23):1877-85. PubMed ID: 20530324
[TBL] [Abstract][Full Text] [Related]
9. [Optimized compliance].
Krankenpfl J; 2005; 43(7-10):238. PubMed ID: 16515308
[No Abstract] [Full Text] [Related]
10. [Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Sørensen S; Koch-Henriksen NJ; Pedersen CR; Clemmesen KM; Bendtzen K; Frederiksen JL; Jensen K; Kristensen O; Petersen T; Rasmussen S; Ravnborg M; Stenager E;
Ugeskr Laeger; 2004 Oct; 166(41):3606-9. PubMed ID: 15515467
[No Abstract] [Full Text] [Related]
11. [Betaferon in the treatment of multiple sclerosis: efficacy standards].
Totolian NA
Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):63-6. PubMed ID: 16117152
[No Abstract] [Full Text] [Related]
12. Guideline for the use of beta-interferons in patients with multiple sclerosis--a South African proposal.
Multiple Sclerosis Advisory Committee of the Neurological Association of South Africa (NASA)
S Afr Med J; 2004 Nov; 94(11):917-21. PubMed ID: 15587456
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta in multiple sclerosis: predicting response at an early stage.
Killestein J; Hartung HP
J Neurol Neurosurg Psychiatry; 2008 Jun; 79(6):616-7. PubMed ID: 18487553
[No Abstract] [Full Text] [Related]
14. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Johnson KP; Due DL
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
[TBL] [Abstract][Full Text] [Related]
15. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
Cohen BA; Rivera VM
Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
[TBL] [Abstract][Full Text] [Related]
16. Interferon antibodies: do they alter the beneficial effects of beta-interferon upon relapse rate in multiple sclerosis?
Rudge P
Mult Scler; 2004 Apr; 10(2):123-5. PubMed ID: 15124755
[No Abstract] [Full Text] [Related]
17. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
[TBL] [Abstract][Full Text] [Related]
18. A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results.
Milanese C; Beghi E; Giordano L; La Mantia L; Mascoli N; Confalonieri P;
Neurol Sci; 2005 Dec; 26 Suppl 4():S171-3. PubMed ID: 16388352
[TBL] [Abstract][Full Text] [Related]
19. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
[TBL] [Abstract][Full Text] [Related]
20. Experiences in treatment of multiple sclerosis with betaferon in federation of Bosnia and Herzegovina.
Mehmedika-Suljic E; Burza-Bosnjak E; Bera M; Hasovic M; Sinanovic O
Med Arh; 2007; 61(1):34-6. PubMed ID: 17582973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]